Richter osteoporosis drug launched in Japan
Hungarian pharmaceutical company Gedeon Richter on Wednesday announced the launch in Japan of the biosimilar teriparatide, developed by its German joint venture Richter Helm BioTec, for the treatment of osteoporosis, Hungarian news agency MTI reports.
Japanʼs Ministry of Health, Labour and Welfare issued marketing authorization for the drug to Richterʼs local license partner Mochida Pharmaceutical in September.
The European Commission approved teriparatide in January 2017 and the product was launched in Europe, under the brand Terrosa, in August 2019, after the patent of the reference product expired.
ADVERTISEMENT
Mapei Targets 6% Higher Revenue This Year
Parliament Negates Mandatory Membership in MOK
Magyar Suzuki to Start Dual Training Courses
Budapest Leaders Unveil Plans to Scale Back Traffic on Thoro...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
